Skip to search formSkip to main contentSkip to account menu

XL184

An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. XL184 strongly binds to and… 
National Institutes of Health

Related topics

Related topics

2 relations
BMS 907351

Broader (1)

cabozantinib s-malate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Use of neurovascular imaging in GBM patients (pts) to quantify early physiologic changes after treatment with XL184, an inhibitor of multiple receptor tyrosine kinases: Results from a phase II study.
2048 Background: Treatment of recurrent glioblastoma by targeting VEGF has gained recent attention. Bevacizumab (bev) or… 
Review
2012
Review
2012
Treatment of Castration-Resistant Prostate Cancer
2012
2012
Abstract SY41-02: Tumor cell effects of vascular reprogramming: Contributions of c-MET and VEGF
Intratumoral hypoxia is associated with greater risk of metastasis and less favorable prognosis. Hypoxia increases the expression… 
2011
2011
Abstract 3587: XL184: c-Met inhibition is effective in a mouse xenograft model of metastatic uveal melanoma
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Oncogenic mutation of GNAQ is an early event in uveal… 
2011
2011
Human Cancer Biology Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors
Purpose:MET signaling has been suggested a potential role inmalignant peripheral nerve sheath tumors (MPNST). Here, MET function… 
2010
2010
Abstract 377: Inhibition of c-Met and VEGFR by XL184 reduces tumor invasiveness and metastasis and prolongs survival of RIP-Tag2 transgenic mice
Recent studies have shown that inhibition of VEGF signaling can promote tumor invasiveness and metastasis in some preclinical… 
2009
2009
Deal watch: Bristol–Myers Squibb and Exelixis collaborate on kinase inhibitors
2009
2009
2008—down, but not out
Researcher Investor Value ($ millions) Deal description Actelion GlaxoSmithKline $3,246.8 Co-develop and co-commercialize phase 3… 
Review
2009
Review
2009
A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse.
2047 Background: XL184 is a potent orally bioavailable inhibitor of MET, RET, KIT, and VEGFR2. Elevated levels of VEGFR2 and its… 
2009
2009
Correlative tumor molecular profiling and plasma biomarker analysis in a phase II study of XL184 in patients with progressive or recurrent glioblastoma multiforme (GBM).
2049 Background: XL184 is an oral inhibitor of MET, RET, KIT, and VEGFR-2 with potent antitumor effects in preclinical models of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)